Use of Growth Hormone in the IVF Treatment of Women With Poor Ovarian Reserve
Growth hormone (GH) has been used as an adjunct in the field of female infertility treatment for more than 25 years, although, apart from treating women with GH deficiency its role has not yet been clarified. Contributing to this lack of clarity is that several underpowered studies have been perform...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-07-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fendo.2019.00500/full |
id |
doaj-7a136bd5bc44474cb15662be5bb7c612 |
---|---|
record_format |
Article |
spelling |
doaj-7a136bd5bc44474cb15662be5bb7c6122020-11-24T22:01:14ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922019-07-011010.3389/fendo.2019.00500465180Use of Growth Hormone in the IVF Treatment of Women With Poor Ovarian ReserveRoger J. Hart0Roger J. Hart1Division of Obstetrics and Gynaecology, University of Western Australia, Perth, WA, AustraliaFertility Specialists of Western Australia, Bethesda Hospital, Claremont, WA, AustraliaGrowth hormone (GH) has been used as an adjunct in the field of female infertility treatment for more than 25 years, although, apart from treating women with GH deficiency its role has not yet been clarified. Contributing to this lack of clarity is that several underpowered studies have been performed on women undergoing IVF treatment, with a previous “poor response” to ovarian stimulation, which have suggested a favorable outcome. Meta-analysis of randomized controlled trials has demonstrated a benefit for the use of the adjunct growth hormone, in comparison to placebo; with reductions in the duration of ovarian stimulation required prior to oocyte retrieval, with a greater number of oocytes collected, and improvements in many of the early clinical parameters with the use of GH. However, no benefit of an increased chance of a live birth with the use of growth hormone for the “poor responding” patient has been determined. Consequently the role of GH to treat a woman with a poor response to ovarian stimulation cannot be supported on the basis of the available evidence. However, the place for GH in the treatment of women undergoing IVF may yet still be determined, as it is also used, without firm evidence of benefit; for women with poor embryonic development, poor endometrial development and for women who do not conceive despite multiple embryo transfers (recurrent implantation failure).https://www.frontiersin.org/article/10.3389/fendo.2019.00500/fullgrowth hormoneIVFovarian reservepoor responderembryo quality |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Roger J. Hart Roger J. Hart |
spellingShingle |
Roger J. Hart Roger J. Hart Use of Growth Hormone in the IVF Treatment of Women With Poor Ovarian Reserve Frontiers in Endocrinology growth hormone IVF ovarian reserve poor responder embryo quality |
author_facet |
Roger J. Hart Roger J. Hart |
author_sort |
Roger J. Hart |
title |
Use of Growth Hormone in the IVF Treatment of Women With Poor Ovarian Reserve |
title_short |
Use of Growth Hormone in the IVF Treatment of Women With Poor Ovarian Reserve |
title_full |
Use of Growth Hormone in the IVF Treatment of Women With Poor Ovarian Reserve |
title_fullStr |
Use of Growth Hormone in the IVF Treatment of Women With Poor Ovarian Reserve |
title_full_unstemmed |
Use of Growth Hormone in the IVF Treatment of Women With Poor Ovarian Reserve |
title_sort |
use of growth hormone in the ivf treatment of women with poor ovarian reserve |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Endocrinology |
issn |
1664-2392 |
publishDate |
2019-07-01 |
description |
Growth hormone (GH) has been used as an adjunct in the field of female infertility treatment for more than 25 years, although, apart from treating women with GH deficiency its role has not yet been clarified. Contributing to this lack of clarity is that several underpowered studies have been performed on women undergoing IVF treatment, with a previous “poor response” to ovarian stimulation, which have suggested a favorable outcome. Meta-analysis of randomized controlled trials has demonstrated a benefit for the use of the adjunct growth hormone, in comparison to placebo; with reductions in the duration of ovarian stimulation required prior to oocyte retrieval, with a greater number of oocytes collected, and improvements in many of the early clinical parameters with the use of GH. However, no benefit of an increased chance of a live birth with the use of growth hormone for the “poor responding” patient has been determined. Consequently the role of GH to treat a woman with a poor response to ovarian stimulation cannot be supported on the basis of the available evidence. However, the place for GH in the treatment of women undergoing IVF may yet still be determined, as it is also used, without firm evidence of benefit; for women with poor embryonic development, poor endometrial development and for women who do not conceive despite multiple embryo transfers (recurrent implantation failure). |
topic |
growth hormone IVF ovarian reserve poor responder embryo quality |
url |
https://www.frontiersin.org/article/10.3389/fendo.2019.00500/full |
work_keys_str_mv |
AT rogerjhart useofgrowthhormoneintheivftreatmentofwomenwithpoorovarianreserve AT rogerjhart useofgrowthhormoneintheivftreatmentofwomenwithpoorovarianreserve |
_version_ |
1725840784035414016 |